Scandinavian Journal of Gastroenterology最新文献

{"title":"Primary intestinal lymphangiectasia across the lifespan: adult-pediatric comparisons of diagnostic delay, immune findings, and treatment patterns.","authors":"Thomas Stirrat, Priyanka Solanky, Shankar Thiru, Lovedeep Singh, Samihaa Mehta, Priyanka Kanth","doi":"10.1080/00365521.2026.2748845","DOIUrl":"https://doi.org/10.1080/00365521.2026.2748845","url":null,"abstract":"<p><p><b>Background</b>: Primary intestinal lymphangiectasia (PIL) is classically considered a pediatric lymphatic disorder, but adult presentation may be under-recognized. <b>Methods</b>: We searched six databases from inception through January 31, 2026, for reports with extractable PIL data. Adult-pediatric comparisons used Mann-Whitney U and Fisher exact tests. <b>Results</b>: After a source-level and eligibility audit, the evidence base comprised 128 individually abstracted primary PIL cases and two author-described pediatric cohorts reported only in aggregate (<i>n</i> = 28 and <i>n</i> = 34); both aggregate cohorts were summarized separately. Among 111 individual cases with age at diagnosis, 58 (52.3%) were adults and 53 (47.7%) were pediatric. Median diagnostic delay was 4.00 years in adults (IQR, 1.00-15.00; <i>n</i> = 30) and 2.21 years in pediatric cases (IQR, 0.69-6.56; <i>n</i> = 30; p = 0.135); delays of at least 10 years occurred in 10/30 (33.3%) and 3/30 (10.0%), respectively (p = 0.057). Baseline albumin was 1.90 g/dL (IQR, 1.60-2.20; <i>n</i> = 93). Individually mapped objective protein-losing enteropathy testing was documented in 37/128 (28.9%), lymphocyte subsets in 20/128 (15.6%), and follow-up duration in 80/128 (62.5%). Diet and medium-chain triglycerides predominated; no estimable treatment or recurrence comparison reached nominal significance. <b>Conclusions</b>: Adult PIL is well represented in published individual cases, but selective reporting and incomplete diagnostic confirmation limit inference. Structured exclusion of secondary etiologies and standardized longitudinal outcomes are needed.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inter-α-inhibitor heavy chain 4 levels in incident and prevalent patients with primary biliary cholangitis.","authors":"Maja Kanstrup Jørgensen, Lars Bossen, Jesper Bach Hansen, Peter Holland-Fischer, Steffen Thiel, Henning Grønbæk","doi":"10.1080/00365521.2026.2748834","DOIUrl":"https://doi.org/10.1080/00365521.2026.2748834","url":null,"abstract":"<p><strong>Background: </strong>Primary biliary cholangitis (PBC) is an autoimmune liver disease characterised by progressive bile duct injury. We recently showed that inter-α-inhibitor heavy chain 4 (ITIH4) levels are elevated in patients with PBC. Here, we investigated the potential of ITIH4 as a biomarker for disease severity and treatment response.</p><p><strong>Methods: </strong>We included 237 patients with primary biliary cholangitis, 80 incident (newly diagnosed), 157 prevalent (with established disease) and 100 healthy controls. All patients were followed for 12 months during initiation or continuation of ursodeoxycholic acid (UDCA). Associations with treatment response, patient type, autoimmune hepatitis (AIH-PBC) and sex were assessed using linear mixed-effects models. The prognostic value of baseline ITIH4 for following response was assessed using logistic regression.</p><p><strong>Results: </strong>ITIH4 levels were significantly higher in both PBC cohorts compared with healthy controls (incident: 274 µg/ml, prevalent: 283 µg/ml, controls: 221 µg/ml; <i>p</i> < .0001). In a mixed-effects model, treatment response, prevalent (vs. incident) disease and AIH-PBC (vs. PBC alone) were each independently associated with lower ITIH4 (<i>p</i> = .003, <i>p</i> = .034 and <i>p</i> = .013). Correlations between ITIH4 and markers of disease severity were generally weak. Baseline ITIH4 was not significantly associated with treatment response (OR 0.994, <i>p</i> = .14).</p><p><strong>Conclusions: </strong>ITIH4 was consistently elevated in patients with PBC compared with healthy individuals. Baseline ITIH4 levels did not independently predict response and correlations with established severity markers remained weak. These findings do not support its use as a prognostic marker or as an addition to existing clinical biomarkers.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining and measuring disease burden in Crohn's disease: a systematic literature review.","authors":"Shellie Jean Radford, B J Olsen, Nurulamin M Noor, Colin John Crooks, Jonathan Segal, James O Lindsay, Remo Panaccione, Gordon Moran","doi":"10.1080/00365521.2026.2745974","DOIUrl":"https://doi.org/10.1080/00365521.2026.2745974","url":null,"abstract":"<p><strong>Objectives: </strong>Crohn's disease (CD) is a chronic, progressive inflammatory bowel disease with evolving disease behaviour, cumulative bowel damage, and long-term impact on patients and health systems. While treat-to-target strategies focus on inflammatory control, disease burden extends beyond active inflammation to include functional, psychosocial, and economic effects. This review aimed to synthesise how disease burden in CD is defined and measured across the literature.</p><p><strong>Methods: </strong>A systematic literature review and narrative synthesis were conducted (PROSPERO protocol CRD420251182987). MEDLINE, EMBASE, CINAHL, and PsycINFO were searched on 3 November 2025 for primary studies involving adults with CD that referenced disease burden. Screening and data extraction were performed in duplicate. Study quality was appraised using Joanna Briggs Institute (JBI) tools and considered during narrative synthesis.</p><p><strong>Results: </strong>Twenty-eight studies from diverse regions and study designs were included. Disease burden was variably defined, encompassing clinical activity, cumulative complications, patient-reported symptoms, functional and societal impact, healthcare utilisation, and population-level epidemiology. Measures clustered into five domains: disease activity and inflammation, patient-reported burden, functional and societal impact, healthcare utilisation and treatment burden, and population-level burden. These domains were typically assessed in isolation, and no study integrated objective clinical measures with patient-reported or quality-of-life outcomes.</p><p><strong>Conclusions: </strong>Disease burden in Crohn's disease is inconsistently defined and measured, reflecting its multidimensional nature but highlighting the absence of an integrated framework. Development of longitudinal, multidimensional tools combining biological, patient-reported, functional, and economic measures is needed to better capture disease burden and support holistic clinical care.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-12"},"PeriodicalIF":1.8,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149207847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity in individuals with inflammatory bowel disease: a Danish population-based repeated cross-sectional study.","authors":"Marie Villumsen, Tanja Thomsen, Anja Poulsen, Tine Jess, Mette Aadahl","doi":"10.1080/00365521.2026.2745977","DOIUrl":"https://doi.org/10.1080/00365521.2026.2745977","url":null,"abstract":"<p><strong>Background: </strong>Existing evidence indicates that physical activity confers health benefits. Nevertheless, the extent of physical activity engagement among individuals with inflammatory bowel disease (IBD) remains unclear. This study aims to quantify physical activity levels and identify socio-demographic and lifestyle factors associated with physical activity levels in adults diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) in comparison to those without IBD.</p><p><strong>Methods: </strong>We included 212,893 participants from the Danish general population who responded to the Danish Capital Region Health Surveys during 2007 to 2021. The population included 2314 individuals with prevalent IBD. Information on physical activity was obtained from self-reported questionnaires and sociodemographic information was obtained from nationwide registers. Data were weighted for survey design and analysed by multiple regression analyses adjusted for sociodemographic factors.</p><p><strong>Results: </strong>The proportion engaging in light, moderate, or high intensity physical activity was lower among participants with CD (80.2%) and UC (83.2%) compared to the non-IBD population (85.6%), even after adjusting the odds ratio (CD: aOR = 0.83; 95% CI 0.80-0.85, UC: aOR = 0.92; 95% CI 0.89-0.95). The severity of IBD accounted for much of this association. Other factors influencing physical activity were similar among participants with and without CD and UC, with the exceptions of gender and smoking.</p><p><strong>Conclusions: </strong>Persons living with IBD, especially those with moderate to severe CD, have lower physical activity levels compared to non-IBD individuals. We identified specific factors associated with lower physical activity that can guide the development of interventions for promoting physical activity in persons with IBD.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aortoduodenal syndrome: evolving management of a rare cause of duodenal obstruction in the endovascular era.","authors":"Nikolaos Koliakos, Anargyros Bakopoulos, Andrianos-Serafeim Tzortzis, Dimitrios Papakonstantinou, Chara Georgiadou, Antreas Lazaris, Dimitrios Schizas","doi":"10.1080/00365521.2026.2745981","DOIUrl":"https://doi.org/10.1080/00365521.2026.2745981","url":null,"abstract":"<p><strong>Objective: </strong>Aortoduodenal syndrome (ADS) is a very rare complication of abdominal aortic aneurysm (AAA), characterized by extrinsic compression of the duodenum leading to proximal bowel obstruction. This systematic review sought to aggregate all published ADS cases, with emphasis on patient demographics, diagnostic workup, treatment modalities, and outcomes.</p><p><strong>Methods: </strong>A systematic literature search was conducted across MedLine/PubMed, Scopus, Embase, and Web of Science from database inception through 2 February 2026, following PRISMA guidelines. Reports containing original patient data describing duodenal obstruction attributable to abdominal aortic aneurysm (AAA), irrespective of rupture status, were eligible for inclusion, provided that the obstruction was attributed to aneurysmal mass effect. Extracted variables included demographic characteristics, clinical presentation, aneurysm morphology, diagnostic imaging, therapeutic interventions, and follow-up results. This study has been registered in PROSPERO (CRD420251456530).</p><p><strong>Results: </strong>Forty studies encompassing 44 patients were analyzed. The cohort was predominantly male (86.6%), with a mean age of 74.5 years. The most common presenting symptoms were vomiting, abdominal pain, and a palpable pulsatile abdominal mass. Computed tomography served as the primary diagnostic tool, whereas upper gastrointestinal contrast series and endoscopy were employed mainly to exclude alternative obstructive etiologies. The third duodenal portion was the most frequently compressed segment, with a median aneurysm diameter of 72.5 mm. Surgical intervention was performed in most patients, comprising open aortic repair (<i>n</i> = 18) or endovascular aneurysm repair (EVAR, <i>n</i> = 13). Gastrointestinal bypass procedures were reserved for selected or salvage situations. Outcome data were available for 42 patients. Mortality was reported in 6 patients (14.3%), including two patients who did not undergo operative treatment. Among the 39 patients who underwent operative treatment, postoperative complications were reported in 9 patients (23.1%).</p><p><strong>Conclusion: </strong>EVAR represents an increasingly reported treatment option in anatomically suitable patients, particularly those at high operative risk; however, the available evidence remains insufficient to establish EVAR as the preferred first-line treatment. Treatment should be individualized according to aneurysm anatomy, clinical condition, operative risk, and severity of duodenal obstruction.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time trends in patients with ulcerative colitis and crohn's disease not receiving IBD-specific pharmacological treatment within one and three years of diagnosis - a nationwide cohort study.","authors":"Mette Wod, Bente Mertz Nørgård, Erantis Sørensen, Jan Nielsen, Jens Kjeldsen","doi":"10.1080/00365521.2026.2745982","DOIUrl":"https://doi.org/10.1080/00365521.2026.2745982","url":null,"abstract":"<p><strong>Background and aims: </strong>Most patients with Crohn's disease (CD) or ulcerative colitis (UC) receive medication at diagnosis, but some do not. We examined 25-year trends in the proportion of newly diagnosed IBD patients not receiving any pharmacologic treatment within one or three years of diagnosis.</p><p><strong>Methods: </strong>Using national health registries, we identified all incident CD and UC patients in Denmark from 1996-2020. IBD-specific medication use was captured from one month before diagnosis through one and three years after diagnosis. Patients with no recorded IBD-specific pharmacological treatment were classified as pharmacologically untreated. Proportions were assessed by age at diagnosis (<18, 18-59, ≥60 years) and calendar period.</p><p><strong>Results: </strong>Among 51,045 incident IBD patients, 21% of those with CD and 12% with UC received no IBD-specific pharmacological treatment within one year of diagnosis. At three years, the corresponding proportions were 16% and 9%. Across calendar periods, the proportion pharmacologically untreated within one year increased from 19% (95% CI 17-21) to 24% (95% CI 22-25) in CD and decreased from 14% (95% CI 12-15) to 10% (95% CI 9-10) in UC. Older patients had the highest proportions.</p><p><strong>Conclusions: </strong>Approximately one in five patients with CD and one in ten patients with UC received no IBD-specific pharmacological treatment in the first year after diagnosis. Over 25 years, this proportion decreased in UC but remained high in CD, especially in older adults. These findings highlight a substantial pharmacologicallyuntreated subgroup and warrant further investigation of the underlying clinical pathways and long-term outcomes.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P-CAB - amoxicillin dual therapy for <i>H. pylori</i> eradication: a narrative review of efficacy, safety, and guideline positioning.","authors":"Youn Su Park","doi":"10.1080/00365521.2026.2745983","DOIUrl":"https://doi.org/10.1080/00365521.2026.2745983","url":null,"abstract":"<p><strong>Background: </strong>Eradication rates of clarithromycin-based standard triple therapy have fallen below 80% in many regions, where primary clarithromycin resistance exceeds 30%. Bismuth-containing quadruple therapy (BQT) and concomitant therapy are limited by regimen complexity, high adverse event rates, and reduced adherence. Potassium-competitive acid blockers (P-CABs) provide rapid, potent acid suppression that is less affected by CYP2C19 polymorphisms than that achieved with PPIs, potentially enhancing the pH-dependent activity of amoxicillin.</p><p><strong>Main text: </strong>Several randomized controlled trials and meta-analyses, largely based on East Asian cohorts, report eradication rates with P-CAB-amoxicillin dual therapy that are non-inferior or superior to BQT. In a network meta-analysis of 25 randomized controlled trials (7,605 patients), P-CAB-amoxicillin dual therapy achieved a pooled ITT eradication rate of 85.2% (95% CI, 83.7-86.7%) and ranked first for combined efficacy and safety (SUCRA, 92.7%). Compared with BQT, it was associated with fewer adverse events (OR, 0.32; 95% CI, 0.28-0.38) and higher compliance (OR, 1.49; 95% CI, 1.26-1.76). The 2024 ACG guideline conditionally suggests vonoprazan-amoxicillin dual therapy as an alternative first-line option, while BQT remains preferred. Maastricht VI/Florence similarly positions P-CAB-amoxicillin dual therapy as an alternative regimen. The 2025 revised Korean guidelines recognize P-CABs as alternatives to PPIs in antibiotic-containing eradication regimens but do not recommend P-CAB-amoxicillin dual therapy as a first-line regimen.</p><p><strong>Conclusions: </strong>P-CAB-amoxicillin dual therapy is a promising, antibiotic-sparing candidate for <i>H. pylori</i> eradication, with efficacy comparable to BQT and a potentially lower adverse-event burden. Comparative evidence against concomitant therapy remains limited. Dedicated regional RCTs are needed before incorporation into national guidelines.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-6"},"PeriodicalIF":1.8,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing management strategies for T4b esophageal cancer: the role of TEVAR in multimodal treatment approaches.","authors":"Nikolaos Koliakos, Andrianos-Serafeim Tzortzis, Dimitrios Papakonstantinou, Evgenia Mela, Natasha Hasemaki, Michail Peroulis, Anargyros Bakopoulos, Dimitrios Schizas","doi":"10.1080/00365521.2026.2745986","DOIUrl":"https://doi.org/10.1080/00365521.2026.2745986","url":null,"abstract":"<p><strong>Background: </strong>T4b esophageal cancer with aortic invasion remains a major therapeutic challenge because treatment-related tumor regression may precipitate aortoesophageal fistula formation and catastrophic hemorrhage. While chemoradiotherapy is the backbone of disease control, the role of thoracic endovascular aortic repair (TEVAR) as prophylaxis or bridge therapy within a multimodal treatment strategy is increasingly recognized.</p><p><strong>Methods: </strong>This narrative review synthesizes current evidence on the use of TEVAR in T4b esophageal cancer. Relevant clinical studies, reviews and guideline documents were evaluated qualitatively, with emphasis on treatment sequencing, bleeding prevention, resectability and oncologic outcomes.</p><p><strong>Results: </strong>Available retrospective studies and systematic reviews suggest that elective TEVAR may reduce the risk of major bleeding complications and facilitate subsequent esophagectomy in selected patients. Elective TEVAR was associated with higher rates of subsequent esophageal resection and fewer complications than salvage TEVAR. Moreover, elective TEVAR followed by esophagectomy, ameliorates significantly patients survival. These findings support the potential role of elective TEVAR within multimodal treatment strategies, although the available evidence remains predominantly retrospective and is subject to selection bias and heterogeneity in patient selection and treatment.</p><p><strong>Conclusions: </strong>TEVAR may represent a useful adjunct in the multimodal management of selected patients with T4b esophageal cancer and aortic involvement. In carefully selected patients, elective TEVAR may reduce the risk of catastrophic hemorrhage and facilitate subsequent curative-intent treatment, including conversion esophagectomy, although prospective evidence defining its optimal indications and timing remains lacking.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-7"},"PeriodicalIF":1.8,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histological characteristics of the lower esophagus among persons with and without GERD in a general population.","authors":"Jennifer Drevin, Peter T Schmidt, Nicholas J Talley, Michael Vieth, Michael P Jones, Bengt Wallner, Per M Hellström, Anna Forsberg, Lars Agréus, Anna Andreasson","doi":"10.1080/00365521.2026.2742236","DOIUrl":"https://doi.org/10.1080/00365521.2026.2742236","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of the study was to describe the mucosal histology of the lower esophagus in a general population and study any differences in histological characteristics between people with (1) no gastroesophageal reflux disease (GERD), i.e., neither symptoms (GERS) nor esophagitis (reference group); (2) non-erosive reflux disease (NERD); (3) no GERS but endoscopic esophagitis; and (4) symptomatic esophagitis, i.e., both GERS and endoscopic esophagitis.</p><p><strong>Materials and methods: </strong>Randomly selected representatives from a general population were eligible for participation and participants (<i>n</i> = 384) underwent an upper gastroduodenoscopy and responded to the Abdominal Symptom Questionnaire. Multinomial logistic regressions were performed.</p><p><strong>Results: </strong>GERS in the last 3 months were reported by 28.4%, and 15.1% had esophagitis. At the Z-line, the median papillae length in the mucosa was 204.8 µm. It was higher in the asymptomatic esophagitis group (<i>m</i> = 262.6 µm), NERD group (<i>m</i> = 220.5 µm), and symptomatic esophagitis group (<i>m</i> = 217.1 µm), compared to the no GERD group (<i>m</i> = 197.4 µm). After adjusting for potential confounders, longer papillae lengths, higher basal layer thickness and total epithelial thickness just above the Z-line increased the likelihood of having symptomatic esophagitis, compared to having no GERD. Individuals with spongiosis 2-3 cm above the Z-line were more likely to have NERD rather than having no GERD (OR = 5.51, CI = 1.53-19.84).</p><p><strong>Conclusion: </strong>This study presents the normal histology of the lower esophagus. There are subtle histological differences in the lower esophagus in people with and without GERS and esophagitis.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic radiofrequency ablation for unresectable cholangiocarcinoma: a single-centre retrospective cohort study with patient interviews.","authors":"Kenan Hajouz, Siri Marie Andersen, Khanh Do-Cong Pham, Inger Marie Løes, Roald Flesland Havre","doi":"10.1080/00365521.2026.2742242","DOIUrl":"https://doi.org/10.1080/00365521.2026.2742242","url":null,"abstract":"<p><strong>Background: </strong>This study assessed biliary drainage durability, survival, and patient experiences following endoscopic retrograde cholangiopancreatography (ERCP)-guided radiofrequency ablation (RFA) plus stenting for palliation in unresectable cholangiocarcinoma (CCA).</p><p><strong>Methods: </strong>Ten patients with unresectable CCA were identified in a single-centre retrospective cohort study conducted in Norway between January 2019 and June 2025. Three surviving patients participated in semi-structured interviews. Primary outcomes were biliary drainage durability, survival, and patient experiences. Secondary outcomes included biliary drainage success, peri-procedural adverse events, biochemical response, and healthcare utilisation.</p><p><strong>Results: </strong>The median time to unplanned biliary reintervention was 218 days, with 3- and 6-month estimates of 79.1% and 56.2%, respectively. The median survival from the first ERCP-RFA was 262 days, with 6- and 12-month estimates of 60.0% and 32.0%, respectively. Interviewed patients reported that feeling fit enough to continue chemotherapy and symptom relief were benefits of ERCP-RFA plus stenting. Post-procedure infection, which reduced time with family, was described as the main burden.</p><p><strong>Conclusion: </strong>ERCP-RFA plus stenting was feasible in this small cohort and was associated with short-term biliary decompression. Interviews indicated a perceived fitness for chemotherapy and meaningful symptom relief. However, frequent readmissions, mainly due to recurrent biliary obstruction, substantially increased the burden of hospital care during palliation. Future studies should evaluate ERCP-RFA plus stenting from a broader palliative perspective using patient-reported outcomes and hospitalisation burden as key endpoints.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}